Authors:
Smaill, JB
Showalter, HDH
Zhou, HR
Bridges, AJ
McNamara, DJ
Fry, DW
Nelson, JM
Sherwood, V
Vincent, PW
Roberts, BJ
Elliott, WL
Denny, WA
Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 18. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido [3,4-d]pyrimidines as soluble, irreversible inhibitors of theepidermal growth factor receptor, J MED CHEM, 44(3), 2001, pp. 429-440
Authors:
Smaill, JB
Rewcastle, GW
Bridges, AJ
Zhou, HR
Showalter, HDH
Fry, DW
Nelson, JM
Sherwood, V
Elliott, WL
Vincent, PW
DeJohn, DE
Loo, JA
Greis, KD
Chan, OH
Reyner, EL
Lipka, E
Denny, WA
Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]-pyrimidine-6-acrylamides bearing additional solubilizing functions(vol 43, pg 1380, 2000), J MED CHEM, 43(16), 2000, pp. 3199-3199
Authors:
Smaill, JB
Palmer, BD
Rewcastle, GW
Denny, WA
McNamara, DJ
Dobrusin, EM
Bridges, AJ
Zhou, HR
Showalter, HDH
Winters, RT
Leopold, WR
Fry, DW
Nelson, JM
Slintak, V
Elliot, WL
Roberts, BJ
Vincent, PW
Patmore, SJ
Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d] pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor, J MED CHEM, 42(10), 1999, pp. 1803-1815
Citation: Jb. Smaill et al., DNA minor groove targeted alkylating agents based on bisbenzimidazole carriers: synthesis, cytotoxicity and sequence-specificity of DNA alkylation, ANTI-CAN DR, 13(8), 1998, pp. 857-880
Authors:
Palmer, BD
Smaill, JB
Boyd, M
Boschelli, DH
Doherty, AM
Hamby, JM
Khatana, SS
Kramer, JB
Kraker, AJ
Panek, RL
Lu, GH
Dahring, TK
Winters, RT
Showalter, HDH
Denny, WA
Citation: Bd. Palmer et al., Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor, J MED CHEM, 41(27), 1998, pp. 5457-5465